Pharmacokinetics, metabolism and excretion of [ 14C]-lenalidomide following oral administration in healthy male subjects

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 3, 2012, Pages 789-797

  Chen, Nianhang ^a   Wen, Lian ^b   Lau, Henry ^a   Surapaneni, Sekhar ^a   Kumar, Gondi ^a  

^a CELGENE CORPORATION   (United States)

^b ABC Laboratories Incorporated   (United States)

Author keywords

Absorption; IMiD; Lenalidomide; Metabolite; Semen; Urinary excretion

Indexed keywords

5 HYDROXYLENALIDOMIDE; CARBON 14; LENALIDOMIDE; N ACETYLLENALIDOMIDE; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ADULT; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; ECG ABNORMALITY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HUMAN; HUMAN EXPERIMENT; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RADIATION DETECTION; RADIOACTIVITY; SINGLE DRUG DOSE; SPERM; STOMACH DISCOMFORT; URINARY EXCRETION;

ABSORPTION; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FECES; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MOLECULAR STRUCTURE; THALIDOMIDE; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84859780661     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1760-3     Document Type: Article

References (20)

1. Knight R (2005) IMiDs: a novel class of immunomodulators. Semin Oncol 32(suppl 5):S24-S30
2. Kotla V, Goel S, Nischal S et al (2009) Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2:36
3. Quach H, Ritchie D, Stewart AK et al (2010) Mechanism of action of immunomodulatory drugs (IMiDs) in multiple myeloma. Leukemia 24:22-32
4. List A, Kurtin S, Roe DJ et al (2005) Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549-557 (Pubitemid 40204668)
5. Melchert M, Kale V, List A (2007) The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes. Curr Opin Hematol 14:123-129 (Pubitemid 46175096)
6. Richardson PG, Blood E, Mitsiades CS et al (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108:3458-3464
7. Wang M, Dimopoulos MA, Chen C et al (2008) Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112:4445-4451
8. Rajkumar SV, Hayman SR, Lacy MQ et al (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:4050-4053 (Pubitemid 41775908)
9. Awan FT, Johnson AJ, Lapalombella R et al (2010) Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 51:27-38
10. Witzig TE, Wiernik PH, Moore T et al (2009) Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 27:5404-5409
11. Habermann TM, Lossos IS, Justice G et al (2009) Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 145:344-349
12. Dalgleish A, Galustian C (2010) The potential of immunomodulatory drugs in the treatment of solid tumors. Future Oncol 6:1479-1484
13. Revlimid® package insert. Celgene Corporation. Revlimid® (lenalidomide)
14. Richardson PG, Schlossman RL, Weller E et al (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063-3067 (Pubitemid 35217050)
15. Chen N, Lau H, Kong L et al (2007) Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47:1466-1475 (Pubitemid 350115306)
16. Kumar G, Lau H, Laskin O (2009) Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction. Cancer Chemother Pharmacol 63:1171-1175
17. Chen N, Lau H, Choudhury S, Wang X, Assaf M, Laskin OL (2010) Distribution of lenalidomide into semen of healthy men after multiple doses. J Clin Pharmacol 50:767-774
18. Amin RP, Fuchs A, Christian MS et al (2009) An embryo-fetal developmental toxicity study of lenalidomide in cynomolgus monkeys. Birth Defects Res A Clin Mol Teratol 85:435
19. Dimopoulos M, Alegre A, Stadtmauer ET et al (2010) The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 116:3807-3814
20. Kumar G, Surapeneni S, Lau H, Laskin O, Fox L (2008) Interaction of lenalidomide with human drug transporters in vitro. Drug Metab Rev S3:282-283